Trident LifelineShare price, financial results, shareholding and management
- Market cap
- ₹490 cr
- Stock P/E
- 25.4peers 19.8
- Book value
- ₹83.6
- Price to book
- 4.90
- EV / operating profit
- -
- Market cap to sales
- 3.80
- ROCE · FY26
- 21.4%
- ROE · FY26
- 23.4%
- ROE, 3-year average
- 17.7%
- Operating margin · FY26
- 21.8%peers 12.7%
- Sales growth, 3 years
- 59.7%
- Profit growth, 3 years
- 47.6%
- Debt to equity
- 0.73peers 0.35
- Borrowings
- ₹73 cr
- Interest cover
- 7.6×
- Cash from business / op. profit
- 18%
- Debtor days
- 209
- Pledged
- 0.00%
- Promoter holding
- 62.46%
- Change in promoter holding
- 0.00 pts
- Shareholders
- 742
- 52-week high / low
- ₹442 / ₹230
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
Trident Lifeline share price chart
Close on 19 Nov 2026 · +2.76% on the day · Vol 4,800
Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 19 Nov 2026
- 1 month
- +2.0%
- 3 months
- +46.5%
- 6 months
- +64.8%
- 1 year
- +31.4%
- Traded a day, 20 days
- ₹0.59 cr
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +48% | +84% |
| 3 years, a year | +60% | +48% |
| Latest half, H2 FY26 | +52% | +81% |
About Trident Lifeline: business, products and customers
Trident Lifeline makes and supplies low cost generic medicines, mostly tablets and capsules, to distributors in Africa, Asia and Latin America and to buyers in India, and is adding injectables, medical devices, supplements and personal care products. Its shares trade on BSE SME.
Trident Lifeline, based in Surat, sells generic tablets, capsules, syrups, ointments and dry powders under its own brands and in bulk through merchant exporters. Before a medicine can be sold abroad it must be registered with that country's health authority, a process the company says takes one and a half to three years and is done jointly with the local customer; the company has been building this bank of registrations since its start in 2014.
It runs a hybrid model: part of the output comes from its own and subsidiary plants and part from contract and loan licence manufacturers, with the company buying the raw and packing materials itself. Buying in finished goods keeps capital needs low but leaves a thinner margin than making them, so the mix moves the gross margin; new plants carry fixed costs before they fill, and customer dues have grown fast, which keeps cash from operations far below profit.
Read more about the business
The prospectus named Vaishali Pharma and Chandra Bhagat Pharma as its listed peers. Sales go to distributors, dealers and B2B partners, with domestic sales now close to half the total, and a part of sales goes to two firms in which directors have an interest.
What is new: an injectables plant (TLL Parenterals) and nutraceuticals (TLL Wellness) expected to start earning in FY27, IV cannulas and infusion sets from Trident Mediquip, the YES personal care brand, planning for a cephalosporin facility (TLL Cefa), 50,000 square metres of land bought, and a preferential issue of shares and warrants approved by the board on 5 October 2026.
From the prospectus (September 2022), the FY26 annual report, the May 2026 investor presentation and exchange announcements of October 2026.
Read the deeper study ↓In its favour
- Sales have grown very fast: 60% a year over three years.
- It earns a high return on the money it uses: ROCE 21% in FY26.
- The promoters own a large part of the company: 62.46%.
To watch
- First revenue from the TLL Parenterals injectables plant and TLL Wellness nutraceuticals, which the company expects in FY27 (Annual report FY26, p.10).
- The preferential issue of equity shares and warrants put to shareholders on 27 October 2026 (exchange announcement, 5 October 2026).
- Conversion of the 2,534 registrations in process into approvals (Annual report FY26, p.16).
- Whether TNS Pharma, which lost ₹3.0 cr in FY26, moves to profit as its plant fills (Annual report FY26, p.40).
- Customers take longer to pay than before: 209 days in FY26, against 97 in FY20.
From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.
Trident Lifeline revenue and profit growth
Half-yearly results · Profit and lossSales have grown very fast. Last year profit grew faster than sales, so the company kept more from each rupee of sales.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew faster than sales.
Trident Lifeline half-yearly results
SME companies report every six months · ₹ crore
| H1FY23 | H2FY23 | H1FY24 | H2FY24 | H1FY25 | H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 13.83 | 17.87 | 18.58 | 26.05 | 29.25 | 49.62 | 53.36 | 75.67 |
| Expenses | 11.50 | 13.94 | 14.62 | 21.82 | 22.05 | 40.18 | 41.33 | · |
| Operating profit | 2.32 | 3.93 | 3.96 | 4.24 | 7.20 | 9.45 | 12.03 | · |
| OPM | 16.8% | 22.0% | 21.3% | 16.3% | 24.6% | 19.0% | 22.5% | · |
| Interest | 0.18 | 0.28 | 0.20 | 0.40 | 0.99 | 2.33 | 2.11 | · |
| Depreciation | 0.12 | 0.24 | 0.29 | 0.68 | 0.70 | 3.50 | 2.37 | · |
| Profit before tax | 2.15 | 4.43 | 4.17 | 4.53 | 6.54 | 7.31 | 10.56 | 16.63 |
| Net profit | 2.02 | 3.99 | 3.11 | 2.83 | 4.41 | 6.33 | 7.88 | 11.44 |
Trident Lifeline profit and loss
Full years to March, FY20 to FY26 · ₹ crore, consolidated where reported
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Sales | 5 | 10 | 22 | 31.69 | 44.63 | 86.97 | 129.02 |
| Expenses | 5 | 8 | 19 | 25.44 | 36.44 | 72.10 | 100.91 |
| Operating profit | 0 | 1 | 3 | 6.25 | 8.19 | 14.86 | 28.11 |
| OPM | -5.0% | 13.0% | 12.0% | 19.7% | 18.4% | 17.1% | 21.8% |
| Other income | 0 | 0 | 1 | 1.16 | 2.08 | 8.23 | 9.27 |
| Interest | 1 | 0 | 0 | 0.47 | 0.60 | 3.98 | 4.12 |
| Depreciation | 0 | 0 | 0 | 0.36 | 0.97 | 5.49 | 6.07 |
| Exceptional and other items | · | · | -1 | · | · | · | · |
| Profit before tax | -1 | 1 | 3 | 6.58 | 8.70 | 13.62 | 27.19 |
| Tax rate | -26.0% | 0.0% | -33.3% | 8.7% | 31.7% | 23.0% | 28.9% |
| Net profit | -1 | 1 | 4 | 6.01 | 5.94 | 10.49 | 19.32 |
| EPS ₹ | -2.58 | 1.26 | 4.94 | 6.23 | 5.17 | 10.22 | 16.32 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
The years to FY22 come rounded to the nearest crore in the source.
Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.
A tax rate above 60% or below zero (FY20, FY22) comes from tax charged on a small or negative profit, as reported.
Trident Lifeline profitability
Margins and returns on capitalLast year the company kept more from each rupee of sales than the year before. It earns a high return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Operating margin | -5.0% | 13.0% | 12.0% | 19.7% | 18.4% | 17.1% | 21.8% |
| Tax rate | -26.0% | 0.0% | -33.3% | 8.7% | 31.7% | 23.0% | 28.9% |
| ROCE | · | 25.0% | 50.0% | 23.1% | 14.9% | 18.5% | 21.4% |
| ROE | · | · | 160.0% | 23.6% | 12.0% | 17.8% | 23.4% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Trident Lifeline debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown fast. Its loans are smaller than its own money. Last year the business brought in less cash than it showed as profit, so part of the profit is still to be collected. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.
Bars below the line are cash going out.
Trident Lifeline balance sheet
At each 31 March · ₹ crore
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Equity capital | 3 | 5 | 8 | 12 | 12 | 12 | 12 |
| Reserves | -6 | -5 | -3 | 34 | 41 | 53 | 88 |
| Net worth | -3 | 0 | 5 | 46 | 53 | 65 | 100 |
| Borrowings | 6 | 5 | 2 | 8 | 18 | 54 | 73 |
| Other liabilities | 3 | 6 | 7 | 9 | 16 | 37 | 63 |
| Total liabilities | 6 | 11 | 14 | 63 | 87 | 156 | 236 |
| Fixed assets | 1 | 1 | 1 | 3 | 21 | 44 | 61 |
| Capital work in progress | 0 | 0 | 0 | 5 | 4 | 2 | 18 |
| Investments | 0 | 0 | 0 | 3 | 4 | 11 | 8 |
| Other assets | 5 | 10 | 13 | 52 | 58 | 99 | 149 |
Trident Lifeline cash flow
₹ crore
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Cash from operations | -1 | 1 | 0 | -19 | 2 | -4 | 5 |
| Cash from investing | 0 | -1 | 0 | -10 | -20 | -14 | -37 |
| Cash from financing | 1 | -1 | 1 | 42 | 11 | 14 | 34 |
| Net cash flow | 0 | -1 | 1 | 13 | -7 | -4 | 2 |
Working capital
Days
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 97 | 24 | 83 | 139 | 110 | 116 | 209 |
| Inventory days | 104 | 349 | 95 | 129 | 156 | 226 | 173 |
| Days payable | 202 | 266 | 134 | 87 | 94 | 119 | 182 |
| Cash conversion cycle | -1 | 107 | 44 | 182 | 173 | 224 | 199 |
| Working capital days | -12 | 12 | 49 | 275 | 205 | 144 | 134 |
Trident Lifeline peers and competitors
Listed SME companies in the same industryBy sales, Trident Lifeline is number 10 of the 34 listed SME companies in pharmaceuticals & biotechnology.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Mono Pharmacare | 16 | 44.6 | 166 | 0.4 | 2.4% | 1.79 |
| Astonea Labs | 341 | 68.1 | 148 | 5 | 9.0% | 0.74 |
| Influx Healthtech | 632 | 30.8 | 147 | 20.5 | 20.3% | 0.00 |
| Jfl Life Sciences | 35 | 5.5 | 131 | 6.4 | 8.9% | 0.47 |
| Trident Lifeline | 490 | 25.4 | 129 | 19.3 | 21.8% | 0.73 |
| Dipna Pharmachem | 11 | 3.5 | 129 | 3 | 3.9% | 0.21 |
| Chandra Bhagat Pharma | 32 | 10.5 | 116 | 3 | 3.3% | 0.50 |
| Quest Laboratories | 154 | 10.3 | 112 | 15 | 16.3% | 0.08 |
| KRM Ayurveda | 573 | 28.6 | 102 | 20 | 30.0% | 0.00 |
| Sotac Pharmaceuticals | 100 | 17.3 | 101 | 5.8 | 17.7% | 0.64 |
| Accretion Pharmaceuticals | 215 | 22.2 | 89.6 | 9.7 | 16.7% | 0.23 |
| Median of the 10 others | 127 | 19.8 | 123 | 6.1 | 12.7% | 0.35 |
Trident Lifeline shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company, a little less than in the first filing shown. Foreign and Indian funds own a noticeable share. The number of shareholders is about the same.
Trident Lifeline shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Aug 26 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 62.99% | 63.04% | 63.04% | 63.10% | 64.11% | 62.86% | 62.46% | 62.46% |
| Foreign investors (FIIs) | 6.09% | 6.62% | 7.21% | 7.71% | 7.04% | 7.24% | - | 4.93% |
| Indian institutions (DIIs) | 0.00% | 0.09% | 0.39% | 0.41% | 0.35% | 0.27% | - | 0.26% |
| Number of shareholders | 523 | 534 | 549 | 554 | 575 | 607 | 742 | 742 |
Trident Lifeline study: the business from its own documents
Read from 8 of the company's own documentsTrident Lifeline key facts from the filings
Each figure with the document it comes from
- Products registered abroad
- 1,091
- Export market registrations at March 2026, with 2,534 more in process across 46 countries.Annual report FY26, p.16
- Registrations planned
- 300 to 400 a year
- New filings the company plans each year; each takes one and a half to three years to clear.Annual report FY26, p.8; Investor presentation, May 2026, p.19
- Domestic share
- 49%
- Share of FY26 revenue sold in India, up from 30% in FY25; Asia led exports.Annual report FY26, p.16
- Tablets and capsules
- 97%
- Tablets gave about 67% and capsules about 30% of FY26 revenue.Annual report FY26, p.16
- Gross margin
- 40.7%
- In FY26, down 6.9 points as material costs rose faster than sales; lower overheads lifted the EBITDA margin instead.Annual report FY26, p.16
Show 5 more facts
- Capacity in use
- 40%
- Utilisation across the group's plants as stated in the FY26 annual report.Annual report FY26, p.4
- Trident Mediquip
- ₹27.3 cr sales
- FY26 turnover of the 59.77% owned medical device arm, with ₹4.3 cr profit after tax.Annual report FY26, p.40
- TNS Pharma
- ₹3.0 cr loss
- FY26 loss after tax of the 51% owned tablet and capsule plant, on ₹5.8 cr of turnover.Annual report FY26, p.40
- Sales to related firms
- ₹15.7 cr
- Sold in FY26 to Tench Lifesciences LLP and Talon Healthcare LLP, in which directors have an interest.Annual report FY26, p.38; our arithmetic
- Customer dues
- ₹49.3 cr
- Standalone trade receivables at March 2026, up from ₹20.4 cr a year earlier.Investor presentation, May 2026, p.30
What the company said, and what happened
The company's own statements, attributed, set against what it later reported; not newboard's estimates
The company says its injectables and nutraceutical businesses should begin contributing revenue from FY27 as their facilities are commissioned and utilisation is built up, that it plans to add 300 to 400 product registrations a year, and that it is planning a cephalosporin facility on newly acquired land. The May 2026 presentation calls the FY27 outlook robust without giving figures. On 5 October 2026 the board approved a preferential issue of equity shares and warrants, to be put to shareholders on 27 October 2026.
Is it a good business? Six questions
Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.
Trident Lifeline earns a spread on low cost generic medicines, and its edge is a large stock of country registrations that take years to build.
Its weak spots are thin pricing power, new plants that are not yet full, sales to related firms and customer dues that have grown faster than sales.
WatchCan it set its own prices?It supplies common generic medicines, so it competes on price and could not pass on all of its higher costs last year.
AverageHow strong is it against rivals?Its registrations are slow for others to copy, but many Indian makers offer the same molecules.
WatchWho are its customers?Sales go to distributors and B2B buyers, a few of which have mattered a lot, and part goes to firms linked to directors.
WatchDoes it need a lot of money?Registrations, new plants and customer credit all take cash, and the company keeps raising equity.
AverageCan it keep finding new work?A long queue of pending registrations and new product lines give room to grow, but approvals clear slowly and the new plants are untested.
AverageDo good and bad years swing a lot?Sales have risen every year, but currency moves, registration timing and plant start ups can shift margins.
Who runs Trident Lifeline?
Promoters, directors and officers; tap a name for the background
HJHardik Jigishkumar DesaiPromoter, Chairman and Executive Director · holds 23.11%
Holds a BCom from South Gujarat University and more than 24 years of experience across the pharmaceutical and textile industries; first joined the board in 2015, rejoined in October 2020 and was named Chairman in June 2022. Oversees the overall management of the company.
Prospectus, p.199; Annual report FY26, p.13 and p.57SHShravan Harikrishna PatelManaging Director
Holds a Master of Urban and Regional Planning from CEPT University; Managing Director since June 2022 and in charge of procurement, sourcing and supply chain, with eight years in the pharmaceutical industry as the annual report states.
Prospectus, p.199; Annual report FY26, p.13RCRupaben Chetan JariwalaPromoter and Whole Time Director · holds 5.30%
A commerce graduate with seven years in pharmaceutical business administration, involved in operational planning and organisational development.
Prospectus, p.1; Annual report FY26, p.13 and p.57MMMayurkumar Mansukhbhai GajeraPromoter · holds 3.98%
Holds an MBA in marketing management and was a Whole Time Director at the time of the IPO, with experience in the pharmaceutical and herbal industry.
Prospectus, p.1 and p.199; Annual report FY26, p.57AAAshish Anandsingh BafnaExecutive Director and Chief Financial Officer
A fellow chartered accountant with more than 27 years in finance and accounting, diplomas in information system audit and computer assisted audit techniques from ICAI, and registration as an insolvency professional.
Annual report FY26, p.13MHManiya Hardik DesaiChief Operating Officer
Holds a BBA in marketing from Manipal Academy of Higher Education and eight years in the pharmaceutical industry; was a non executive director at the time of the IPO.
Prospectus, p.199; Annual report FY26, p.13SKSmita Kiran DavdaIndependent Director
A chartered accountant with more than 23 years in banking and financial services, including senior roles at Yes Bank.
Annual report FY26, p.13SBSachin BhandariIndependent Director
Holds an MBA and BCom and more than 25 years in the pharmaceutical industry in quality systems, regulatory compliance and digital transformation at UCB Pharma, Boehringer Ingelheim, Sun Pharma, Reckitt Benckiser and GSK.
Annual report FY26, p.13Trident Lifeline latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹75.7 cr (+52%), net profit ₹11.4 cr (+81%) on H2 FY25.
- Shareholding, 31 Aug 2026: promoters unchanged at 62.46%.
Trident Lifeline announcements
20 on record, latest first; each opens the filing on the exchange
- Company UpdatePlease find enclosed Press Release titled 'CPHI Milan 2026: Opening doors to regulated markets and new global business opportunities' issued on October 09, 2026PDF ↗
- Company UpdatePlease find enclosed herewith the Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 as received from MUFG Intime IndiPDF ↗
- Company UpdatePlease find attached herewith copies of newspaper advertisements published in the Financial Express (English) and Financial Express (Gujarati), regarding noticePDF ↗
- Company UpdateThis is in continuation of the Outcome of the Board Meeting submitted by the Company to the Exchange on October 05, 2026 regarding the Board Meeting held on OctPDF ↗
- AGM/EGMWe would like to inform you that the Extra-Ordinary General Meeting is scheduled to be held on Tuesday, October 27, 2026, at 04.00 p.m.(IST) through Video ConfePDF ↗
- Company UpdateThe Board of Director has approved the alteration of Article of Association, subject to the approval of MembersPDF ↗
- Company UpdateTrident Lifeline Limited has announced the issue of Equity shares and Warrants on preferential basisPDF ↗
- Board MeetingOutcome of Board Meeting held on 05.10.2026PDF ↗
- Company UpdatePursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, we would like tPDF ↗
- Company UpdatePursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome oPDF ↗
- Insider Trading / SASTWith reference to our letter dated September 29, 2026 and Pursuant to SEBI (Prohibition of Insider Trading) Regulation, 2015, we wish to inform you that the TraPDF ↗
- Company UpdateWe wish to inform to the Exchange that Trident Lifeline Limited has made further Investment by acquiring an additional equity stake of 1.00% of TRIDENT MEDIQUIPPDF ↗
Trident Lifeline annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
- Offer document ↗read
Trident Lifeline share split, bonus and dividends
From the corporate actions the company announces on the exchange
No share split, bonus issue or dividend is on record since listing.
Checks we ran on Trident Lifeline's data · 9
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- !The two halves of FY25 as reported add up to sales of ₹78.88 cr, the full year to ₹86.97 cr; one of the filings may have been restated.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (1,19,57,000 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- ✓Earnings per share moves in line with profit across the years shown.
- ✓Revenue and profit are reported for every year shown, FY20 to FY26.
- iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.
Questions people ask about Trident Lifeline
What does Trident Lifeline do?
Trident Lifeline makes and supplies low cost generic medicines, mostly tablets and capsules, to distributors in Africa, Asia and Latin America and to buyers in India, and is adding injectables, medical devices, supplements and personal care products. Its shares trade on BSE SME.
What is the share price of Trident Lifeline?
₹410 at the close on 19 Nov 2026, from the exchange's daily figures.
What is the market cap of Trident Lifeline?
₹490 cr at the close on 19 Nov 2026, on 1,19,57,000 shares.
What is the P/E of Trident Lifeline?
25.4 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).
What are Trident Lifeline's revenue and profit?
Revenue ₹129 cr and profit after tax ₹19 cr in FY26.
Who are the promoters of Trident Lifeline?
Hardik Jigishkumar Desai, Rupaben Chetan Jariwala, Mayurkumar Mansukhbhai Gajera; promoters held 62.46% at 31 Aug 2026.
What is Trident Lifeline's website?
www.tridentlifeline.com
More SME companies like Trident Lifeline
Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.
- KRM AyurvedaKRMAYURVED · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2026Market cap ₹476 cr
- Infinium PharmachemINFINIUM · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2023Market cap ₹464 cr
- Astonea LabsASTONEALAB · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹431 cr
- Influx HealthtechINFLUX · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2025Market cap ₹644 cr
- Aptus PharmaAPPL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹820 cr
- Remus PharmaceuticalsREMUS · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2023Market cap ₹937 cr
Every listed SME company in Pharmaceuticals & Biotechnology →
Built from 3 investor presentations, 3 annual reports, 1 offer document, 1 press release, 20 exchange announcements, 8 shareholding patterns and 7 years of reported results. Every figure carries its source; where the documents are silent, the page says so.